JP2020511469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511469A5 JP2020511469A5 JP2019550688A JP2019550688A JP2020511469A5 JP 2020511469 A5 JP2020511469 A5 JP 2020511469A5 JP 2019550688 A JP2019550688 A JP 2019550688A JP 2019550688 A JP2019550688 A JP 2019550688A JP 2020511469 A5 JP2020511469 A5 JP 2020511469A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- effective amount
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030606A JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US62/471,190 | 2017-03-14 | ||
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| US62/553,059 | 2017-08-31 | ||
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030606A Division JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511469A JP2020511469A (ja) | 2020-04-16 |
| JP2020511469A5 true JP2020511469A5 (https=) | 2021-04-22 |
| JP7293122B2 JP7293122B2 (ja) | 2023-06-19 |
Family
ID=61873979
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550688A Active JP7293122B2 (ja) | 2017-03-14 | 2018-03-14 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2023030606A Pending JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A Pending JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030606A Pending JP2023071824A (ja) | 2017-03-14 | 2023-03-01 | 補体が媒介する疾患および障害を処置するための方法 |
| JP2025014511A Pending JP2025072437A (ja) | 2017-03-14 | 2025-01-31 | 補体が媒介する疾患および障害を処置するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210115116A1 (https=) |
| EP (1) | EP3596121A1 (https=) |
| JP (3) | JP7293122B2 (https=) |
| KR (2) | KR20260039796A (https=) |
| CN (1) | CN110753701A (https=) |
| AU (2) | AU2018236267B2 (https=) |
| BR (1) | BR112019018950A2 (https=) |
| CA (1) | CA3055781A1 (https=) |
| CR (1) | CR20190468A (https=) |
| IL (2) | IL325084A (https=) |
| MX (2) | MX2019010994A (https=) |
| SG (1) | SG11201907583TA (https=) |
| TW (2) | TW202513092A (https=) |
| WO (1) | WO2018170145A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2016164358A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| HUE073475T2 (hu) | 2016-10-12 | 2026-01-28 | Bioverativ Usa Inc | C1s elleni antitestek és alkalmazási eljárásaik |
| WO2020121282A1 (en) | 2018-12-13 | 2020-06-18 | Argenx Bvba | Antibodies to human complement factor c2b and methods of use |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| WO2021108447A1 (en) * | 2019-11-26 | 2021-06-03 | Omeros Corporation | Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant |
| FI129383B (en) * | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| IL300376A (en) | 2020-08-06 | 2023-04-01 | Bioverativ Usa Inc | Inflammatory cytokines and fatigue in subjects with complement-mediated disease |
| CN117241828A (zh) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | 减少冷凝集素病患者的手术相关溶血 |
| CN117769434A (zh) | 2021-05-20 | 2024-03-26 | 黛安瑟斯医疗运营公司 | 与C1s结合的抗体和其用途 |
| US11958899B2 (en) | 2021-07-13 | 2024-04-16 | Mabwell Therapeutics Inc. | Anti-C1s antibodies and uses thereof |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| IL317947A (en) * | 2022-06-24 | 2025-02-01 | Bioverativ Usa Inc | Complementary disease treatment methods |
| AU2023385709A1 (en) | 2022-11-21 | 2025-06-12 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to c1s and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| DK2914291T3 (da) * | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 KR KR1020267006425A patent/KR20260039796A/ko active Pending
- 2018-03-14 CR CR20190468A patent/CR20190468A/es unknown
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/es unknown
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/ja active Active
- 2018-03-14 TW TW113122096A patent/TW202513092A/zh unknown
- 2018-03-14 BR BR112019018950-5A patent/BR112019018950A2/pt unknown
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/zh active Pending
- 2018-03-14 KR KR1020197029545A patent/KR102934707B1/ko active Active
- 2018-03-14 TW TW107108658A patent/TWI848905B/zh active
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
- 2018-03-14 IL IL325084A patent/IL325084A/en unknown
-
2019
- 2019-09-08 IL IL269174A patent/IL269174B1/en unknown
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/es unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/ja active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/ja active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511469A5 (https=) | ||
| JP7628996B2 (ja) | 改善された血清アルブミン結合剤 | |
| US20240124599A1 (en) | Anti-bcma heavy chain-only antibodies | |
| US10618976B2 (en) | SIRP-α agonist antibody | |
| US11434299B2 (en) | Anti-BCMA heavy chain-only antibodies | |
| US20240117046A1 (en) | Heavy chain antibodies binding to cd22 | |
| JP2018520139A (ja) | エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法 | |
| JP2026053563A (ja) | 補体関連疾患のための融合タンパク質構築物 | |
| KR20230021773A (ko) | 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도 | |
| CN112442123B (zh) | 抗cd47的单克隆抗体及其用途 | |
| CN111630065A (zh) | 抗c5抗体组合及其用途 | |
| EP3313417A1 (en) | Methods of treating autoimmune and alloimmune disorders | |
| JP7158376B2 (ja) | インターロイキン－６のヒト受容体に結合することができる抗体またはその抗原結合フラグメント | |
| RU2824402C2 (ru) | Конструкции слитого белка для заболевания, связанного с комплементом | |
| WO2025128263A9 (en) | Anti-pd-1 monoclonal antibody and methods of preparation thereof | |
| HK40125060A (zh) | 用於抗c1q抗体的制剂 | |
| NZ749153A9 (en) | Anti-c5 antibodies and uses thereof | |
| NZ749153B2 (en) | Anti-c5 antibodies and uses thereof | |
| BR112016025319B1 (pt) | Anticorpo anti-fcrn isolado, polinucleotídeos, vetor de expressão recombinante, composições e método para detectar fcrn in vitro |